EMA Authorised: Kineret (anakinra) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

New authorisation of Kineret (anakinra) for rheumatoid arthritis and COVID-19 infection in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• KINERET (ANAKINRA)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;COVID-19 virus infection. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 04/09/2025